Facilitated cascade testing (FaCT): a randomized controlled trial
Identifying mutation-carrying relatives of patients with hereditary cancer syndromes via cascade testing is an underused first step in primary cancer prevention. A feasibility study of facilitated genetic testing of at-risk relatives of patients with a known pathogenic mutation demonstrated encouraging uptake of cascade testing. Our primary objective is to compare the proportion of genetic testing of identified first-degree relatives of probands with a confirmed We hypothesize that facilitated cascade testing will drive significantly higher uptake of genetic testing than the standard of care. The FaCT (Facilitated Cascade Testing) trial is a prospective multi-institutional randomized study comparing the efficacy of a multicomponent facilitated cascade testing intervention with the standard of care. Patients with a known Adult participants who are first-degree relatives of a patient with a Analyses will assess the proportion of first-degree relatives identified by the proband who complete genetic testing by 6 months in the intervention arm versus the control arm. One hundred and fifty probands with a BRCA1/2 mutation will be randomized. Each proband is expected to provide an average of 3 relatives, for an expected 450 participants. January 2024. NCT04613440.
Authors
Funding
Training of Academic Gynecologic OncologistsCancer Center Support GrantInstitutional Career Development CorePathologyClinical and Translational Science CenterI. Institutional Career Development CoreObstetrical and Oncological Outcomes Among Reproductive Age Women with Gynecological and Breast CancerNational Center for Advancing Translational Sciences Grant KL2TR001874Training of Academic Gynecologic OncologistsObstetrical and Oncological Outcomes Among Reproductive Age Women with Gynecological and Breast CancerThe National Institutes of Health National Cancer Institute Grant P30 48CA016672National Center for Advancing Translational Sciences Grant KL2-TR-002385